menu
    • menu
    [{"orgOrder":0,"company":"RayzeBio","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"RayzeBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"RayzeBio \/ venBio Partners","highestDevelopmentStatusID":"1","companyTruncated":"RayzeBio \/ venBio Partners"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Actinium pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.57999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.57999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Fusion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Fusion Pharmaceuticals"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NorthStar Medical Radioisotopes \/ POINT","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ POINT"},{"orgOrder":0,"company":"Bayer AG","sponsor":"BWXT Medical Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ BWXT Medical Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ BWXT Medical Ltd."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Point Biopharma \/ IONETIX Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ IONETIX Corporation"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Actinium pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ablaze Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Ablaze Pharma \/ Vivo Capital","highestDevelopmentStatusID":"12","companyTruncated":"Ablaze Pharma \/ Vivo Capital"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Yonghe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ablaze Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ablaze Pharma \/ Yonghe Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Ablaze Pharma \/ Yonghe Pharma"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Cancer Science Institute of Singapore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Cancer Science Institute of Singapore","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ Cancer Science Institute of Singapore"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ J.P. Morgan"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BWX Technologies \/ Fusion Pharma","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ Fusion Pharma"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abdera Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Actinium-225

    Menu

    Actinium-225

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Abdera Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Abdera Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Abdera Gets FDA Orphan Drug Designation For ABD-147 in Neuroendocrine Carcinoma

                            Details : ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of large cell neuroendocrine carcinoma.

                            Brand Name : ABD-147

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 05, 2024

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Abdera Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Abdera Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Abdera Therapeutics Gets FDA Fast Track Designation for ABD-147 in Small Cell Lung Cancer

                            Details : ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225, it is being investigated in extensive stage small cell lung cancer expressing DLL3.

                            Brand Name : ABD-147

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 27, 2024

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Abdera Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Abdera Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147

                            Details : ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of small cell lung cancer and large cell neuroendocrine carcinoma.

                            Brand Name : ABD-147

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 23, 2024

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BWX Technologies

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BWX Technologies

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Fusion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            BWXT Medical Expands Collaboration with Fusion Pharmaceuticals through Strengthened Actinium Supply and Access...

                            Details : Under the agreement, BWXT Medical, will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology, enabling Fusion for advancing its pipeline of targeted alpha therapies.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 16, 2023

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Fusion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RayzeBio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RYZ801,Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            RayzeBio Announces Initial Public Offering

                            Details : The proceeds will advance IND enabling activities and clinical development of RYZ801, a novel proprietary peptide which targets GPC3 for delivery of Ac225, and RYZ811 in HCC through Phase 1b safety data and the development of RYZ101 for GEP-NETs and exte...

                            Brand Name : RYZ801

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            August 25, 2023

                            Lead Product(s) : RYZ801,Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Monopar Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Monopar Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MNPR-101,Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Cancer Science Institute of Singapore

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

                            Details : The collaboration aims to evaluate radiopharmaceutical versions of MNPR-101 RIT in several aggressive cancers. MNPR-101 is a novel, first-in-class humanized monoclonal antibody to the urokinase Plasminogen Activator Receptor (uPAR).

                            Brand Name : MNPR-101 RIT

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 11, 2023

                            Lead Product(s) : MNPR-101,Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Cancer Science Institute of Singapore

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RayzeBio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            RayzeBio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroen...

                            Details : RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2.

                            Brand Name : RYZ101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 20, 2023

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ablaze Pharma

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ablaze Pharma

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Yonghe Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targete...

                            Details : Actinium-225 is an alpha emitting radioactive particle that has high energy density acting at distances of just a few cell widths. At these short distances, radiation can be restricted to the cancer cells of interest with minimal risk to nearby normal he...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 27, 2022

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Yonghe Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Point Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Point Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EA...

                            Details : PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225.

                            Brand Name : PNT2001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 17, 2022

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ablaze Pharma

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ablaze Pharma

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Vivo Capital

                            Deal Size : $75.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to T...

                            Details : Proceeds from the financing will be used by Ablaze to establish a leading pipeline of advanced TRT products having Actinium-225 for the treatment of solid tumors, build up infrastructure for radiopharmaceuticals and secure further strategic collaboration...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 29, 2021

                            Lead Product(s) : Actinium-225

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Vivo Capital

                            Deal Size : $75.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth